{"id":390859,"date":"2017-11-14T00:00:00","date_gmt":"2017-11-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0016-biopharma-ulcerative-colitis-current-treatment-physician-insights-eu5-2017\/"},"modified":"2026-04-15T09:57:31","modified_gmt":"2026-04-15T09:57:31","slug":"cutrim0016-biopharma-ulcerative-colitis-current-treatment-physician-insights-eu5-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0016-biopharma-ulcerative-colitis-current-treatment-physician-insights-eu5-2017\/","title":{"rendered":"Ulcerative Colitis | Current Treatment: Physician Insights | EU5 | 2017"},"content":{"rendered":"<p>The primary goals of pharmacotherapy in <abbr title=\"ulcerative colitis\">UC<\/abbr> are to induce remission during acute flares and to maintain long-term corticosteroid-free remission, once remission is achieved. <abbr title=\"ulcerative colitis\">UC<\/abbr> treatment regimens are broadly divided into acute and maintenance therapy. Acute therapies are used to induce remission and to inhibit the inflammatory process, whereas maintenance therapies support remission and prevent acute flares. The treatment of <abbr title=\"ulcerative colitis\">UC<\/abbr> generally starts with conventional small molecules like 5-<abbr title=\"aminosalicylate\">ASA<\/abbr>s, which are the mainstay of <abbr title=\"ulcerative colitis\">UC<\/abbr> treatment. Patients not controlled on 5-<abbr title=\"aminosalicylate\">ASA<\/abbr>s are commonly prescribed corticosteroids and immunosuppressants. Biologics are generally reserved for uncontrolled moderate to severe <abbr title=\"ulcerative colitis\">UC<\/abbr> patients,\u00a0and surgery is the last resort when a <abbr title=\"ulcerative colitis\">UC<\/abbr> patient does not respond to any treatments. Among the biologics, <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors\u2014especially Remicade and Humira\u2014are the most prescribed drugs. The recent launch of biosimilar infliximab\u2014a less-expensive alternative to Remicade\u2014has altered how some physicians make their prescribing decisions for <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors. The launch of drugs with newer <abbr title=\"mechanism of action\">MOA<\/abbr>s, including the <abbr title=\"cell adhesion molecule\">CAM<\/abbr> inhibitor Entyvio, has further impacted the\u00a0<abbr title=\"ulcerative colitis\">UC<\/abbr> treatment landscape.<\/p>\n","protected":false},"template":"","class_list":["post-390859","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ulcerative-colitis","biopharma-product-current-treatment","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390859\/revisions"}],"predecessor-version":[{"id":393983,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390859\/revisions\/393983"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}